Sanj K. Patel, President & CEO at SYNAGEVA BIOPHARMA CORP (GEVA), sold 102,300 shares at $90.10 ($9.0M) on 2014-01-28, disclosed to the SEC on 2014-01-30.
Scheduled sale ($9.0M) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $87.16 | 9,506 | $829K | 9.2% |
| 2 | $88.38 | 32,609 | $2.9M | 32.0% |
| 3 | $88.95 | 8,402 | $747K | 8.3% |
| 4 | $90.10 | 812 | $73K | 0.8% |
| 5 | $87.19 | 24,817 | $2.2M | 24.0% |
| 6 | $88.31 | 18,652 |
| $1.6M |
| 18.3% |
| 7 | $89.27 | 5,600 | $500K | 5.5% |
| 8 | $90.85 | 1,502 | $136K | 1.5% |
| 9 | $91.58 | 400 | $37K | 0.4% |
| Total | $88.12 avg | 102,300 | $9.0M | 100% |
| Filing → |
| KNSA | SELL | 2026-04-08 | $364K | — | Filing → |
| KNSA | SELL | 2025-10-22 | $20.0M | — | Filing → |
| KNSA | SELL | 2025-05-28 | $4.6M | — | Filing → |